CANF
Can-Fite BioPharmaCANF
CANF
About: Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Employees: 5
0
Funds holding %
of 7,324 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
8% more funds holding
Funds holding: 13 [Q4 2024] → 14 (+1) [Q1 2025]
4% more capital invested
Capital invested by funds: $186K [Q4 2024] → $194K (+$7.94K) [Q1 2025]
0% more ownership
Funds ownership: 0% [Q4 2024] → 0% (+0%) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
1,393%
upside
Avg. target
$10
1,393%
upside
High target
$10
1,393%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 1,393%upside $10 | Buy Maintained | 29 Jul 2025 |
Financial journalist opinion
Based on 3 articles about CANF published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone
Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer.
Neutral
GlobeNewsWire
3 days ago
Can-Fite Announces Up To $15.0 Million Public Offering
$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Neutral
GlobeNewsWire
3 days ago
Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia
Ramat Gan, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that a leading group from University of Los Angeles (UCLA), demonstrate that Piclidenoson showed efficacy in an experimental model of vascular dementia.
Neutral
GlobeNewsWire
3 months ago
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that leading Medical Centers in the US are approaching the FDA, asking for compassionate use approval to treat patients with pancreatic carcinoma with the company oncological drug Namodenoson.
Neutral
GlobeNewsWire
3 months ago
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases (“Can-Fite” or the “Company”), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 of the Company's American Depositary Shares (“ADSs”), at a purchase price of $1.20 per ADS, in a registered direct offering. The offering is expected to close on or about April 15, 2025, subject to satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
4 months ago
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Can-Fite's upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch
Neutral
GlobeNewsWire
4 months ago
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients
Neutral
GlobeNewsWire
4 months ago
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effects Ramat Gan, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the European Society of Medicine Journal published an innovative article titled: “The Neuro- Cardio- and Hepato- Protective Effects of Namodenoson are Mediated by Adiponectin”.
Neutral
GlobeNewsWire
5 months ago
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25
RAMAT GAN, Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on Tuesday, February 25, 2025, at 4:15 p.m. ET.
Neutral
GlobeNewsWire
5 months ago
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
Ramat Gan, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York City.
Charts implemented using Lightweight Charts™